521 related articles for article (PubMed ID: 33142841)
1. Past, Present and Future of Oncolytic Reovirus.
Müller L; Berkeley R; Barr T; Ilett E; Errington-Mais F
Cancers (Basel); 2020 Oct; 12(11):. PubMed ID: 33142841
[TBL] [Abstract][Full Text] [Related]
2. New hopes for the breast cancer treatment: perspectives on the oncolytic virus therapy.
Chowaniec H; Ślubowska A; Mroczek M; Borowczyk M; Braszka M; Dworacki G; Dobosz P; Wichtowski M
Front Immunol; 2024; 15():1375433. PubMed ID: 38576614
[TBL] [Abstract][Full Text] [Related]
3. Emerging systemic delivery strategies of oncolytic viruses: A key step toward cancer immunotherapy.
Ban W; Guan J; Huang H; He Z; Sun M; Liu F; Sun J
Nano Res; 2022; 15(5):4137-4153. PubMed ID: 35194488
[TBL] [Abstract][Full Text] [Related]
4. Oncolytic virotherapy evolved into the fourth generation as tumor immunotherapy.
Wang X; Shen Y; Wan X; Hu X; Cai WQ; Wu Z; Xin Q; Liu X; Gui J; Xin HY; Xin HW
J Transl Med; 2023 Jul; 21(1):500. PubMed ID: 37491263
[TBL] [Abstract][Full Text] [Related]
5. Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade.
Marchini A; Scott EM; Rommelaere J
Viruses; 2016 Jan; 8(1):. PubMed ID: 26751469
[TBL] [Abstract][Full Text] [Related]
6. Immunovirotherapy: The role of antibody based therapeutics combination with oncolytic viruses.
Jafari M; Kadkhodazadeh M; Shapourabadi MB; Goradel NH; Shokrgozar MA; Arashkia A; Abdoli S; Sharifzadeh Z
Front Immunol; 2022; 13():1012806. PubMed ID: 36311790
[TBL] [Abstract][Full Text] [Related]
7. The Role of Oncolytic Viruses in the Treatment of Melanoma.
Bayan CY; Lopez AT; Gartrell RD; Komatsubara KM; Bogardus M; Rao N; Chen C; Hart TD; Enzler T; Rizk EM; Pradhan JS; Marks DK; Geskin LJ; Saenger YM
Curr Oncol Rep; 2018 Aug; 20(10):80. PubMed ID: 30145781
[TBL] [Abstract][Full Text] [Related]
8. Giving Oncolytic Viruses a Free Ride: Carrier Cells for Oncolytic Virotherapy.
Reale A; Calistri A; Altomonte J
Pharmaceutics; 2021 Dec; 13(12):. PubMed ID: 34959474
[TBL] [Abstract][Full Text] [Related]
9. Talimogene Laherparepvec (T-VEC): A Review of the Recent Advances in Cancer Therapy.
Zhang T; Jou TH; Hsin J; Wang Z; Huang K; Ye J; Yin H; Xing Y
J Clin Med; 2023 Jan; 12(3):. PubMed ID: 36769745
[TBL] [Abstract][Full Text] [Related]
10. Review: Oncolytic virotherapy, updates and future directions.
Fountzilas C; Patel S; Mahalingam D
Oncotarget; 2017 Nov; 8(60):102617-102639. PubMed ID: 29254276
[TBL] [Abstract][Full Text] [Related]
11. Oncolytic virotherapy as promising immunotherapy against cancer: mechanisms of resistance to oncolytic viruses.
Goradel NH; Alizadeh A; Hosseinzadeh S; Taghipour M; Ghesmati Z; Arashkia A; Negahdari B
Future Oncol; 2022 Jan; 18(2):245-259. PubMed ID: 34821517
[TBL] [Abstract][Full Text] [Related]
12. Therapy with oncolytic viruses: progress and challenges.
Shalhout SZ; Miller DM; Emerick KS; Kaufman HL
Nat Rev Clin Oncol; 2023 Mar; 20(3):160-177. PubMed ID: 36631681
[TBL] [Abstract][Full Text] [Related]
13. The Multifaceted Role of Macrophages in Oncolytic Virotherapy.
Hofman L; Lawler SE; Lamfers MLM
Viruses; 2021 Aug; 13(8):. PubMed ID: 34452439
[TBL] [Abstract][Full Text] [Related]
14. Emerging Nano-/Biotechnology Drives Oncolytic Virus-Activated and Combined Cancer Immunotherapy.
Fang C; Xiao G; Wang T; Song L; Peng B; Xu B; Zhang K
Research (Wash D C); 2023; 6():0108. PubMed ID: 37040283
[TBL] [Abstract][Full Text] [Related]
15. Perspectives on immunotherapy via oncolytic viruses.
Reale A; Vitiello A; Conciatori V; Parolin C; Calistri A; Palù G
Infect Agent Cancer; 2019; 14():5. PubMed ID: 30792754
[TBL] [Abstract][Full Text] [Related]
16. Preexisting immunity: Barrier or bridge to effective oncolytic virus therapy?
Groeneveldt C; van den Ende J; van Montfoort N
Cytokine Growth Factor Rev; 2023 Apr; 70():1-12. PubMed ID: 36732155
[TBL] [Abstract][Full Text] [Related]
17. Immune System, Friend or Foe of Oncolytic Virotherapy?
Filley AC; Dey M
Front Oncol; 2017; 7():106. PubMed ID: 28589085
[TBL] [Abstract][Full Text] [Related]
18. OV Modulators of the Paediatric Brain TIME: Current Status, Combination Strategies, Limitations and Future Directions.
Vazaios K; van Berkum RE; Calkoen FG; van der Lugt J; Hulleman E
Int J Mol Sci; 2024 May; 25(9):. PubMed ID: 38732225
[TBL] [Abstract][Full Text] [Related]
19. Oncolytic Viruses for Cancer Therapy: Barriers and Recent Advances.
Zheng M; Huang J; Tong A; Yang H
Mol Ther Oncolytics; 2019 Dec; 15():234-247. PubMed ID: 31872046
[TBL] [Abstract][Full Text] [Related]
20. The Current Status and Future Prospects of Oncolytic Viruses in Clinical Trials against Melanoma, Glioma, Pancreatic, and Breast Cancers.
Eissa IR; Bustos-Villalobos I; Ichinose T; Matsumura S; Naoe Y; Miyajima N; Morimoto D; Mukoyama N; Zhiwen W; Tanaka M; Hasegawa H; Sumigama S; Aleksic B; Kodera Y; Kasuya H
Cancers (Basel); 2018 Sep; 10(10):. PubMed ID: 30261620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
